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OBJECTIVES: Post-transplant patients have high risk of re-hospitalization, incurring 
relevant costs. The aim of this study is to analyze causes, resource use and costs of 
re-hospitalizations in a cohort of renal transplanted patients. METHODS: A longitu-
dinal analysis of a government administrative database (Inpatient Information 
System—SIH/DATASUS) was performed from January 2004 to July 2009. The study 
cohort was all patients who had undergone kidney transplant at 7 of the main trans-
plant hospitals in Brazil, in 2004. All patients were followed until July 2009. Demo-
graphic data (sex, age, type of donor), length of re-hospitalization, resource use and 
associated costs (in 2004 USD) were collected. RESULTS: A total of 1030 patients 
were eligible for the analysis. Mean age was 38.7 ± 14.5 years, 57.6% were male 
recipients and 49.6% of transplant procedures were from living donors. During the 
study period 2,168 hospitalizations occurred in 643 patients (62%), with a total cost 
of US$ 1,568,956. Most frequent causes of re-hospitalization were post-transplant 
surgical and clinical complications (40.1%) and graft rejection episodes (32.4%), 
accounting together for 76.9% (US$ 1,207,406) of total expenses. Hospital services 
(ICU/Ward days, operation room, equipments, etc) represent the most signiﬁcant part 
of re-hospitalization costs (40.9%), followed by diagnostic/laboratory exams (24.2%), 
medicines (13.6%) and health professional fees (11.0%). Re-hospitalizations were 
concentrated in the ﬁrst (39.6%) and second (24.0%) years following transplant, 
stabilizing in the fourth and ﬁfth years around 9% (200 hospitalizations/year). Patients 
receiving grafts from deceased donors accounted for 68.4% of total costs, and average 
costs per re-hospitalization were statistically different between patients receiving grafts 
from deceased (US$ 778 ± 1,181) relative to living donors (US$ 632 ± 973) (p < 0.01). 
CONCLUSIONS: The majority of patients who underwent kidney transplant in 2004 
were re-hospitalized at least once until July 2009. Costs associated with these re-
hospitalizations were concentrated in the ﬁrst year post-transplant and in cadaveric 
renal transplant recipients.
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OBJECTIVES: Graft rejection episodes are important causes of hospitalization in 
post-kidney transplant patients. The aim of this study is to analyze the incidence of 
rejection episodes (REs) requiring hospitalization after renal transplant, associated 
resource use and costs for the Brazilian Public Health System. METHODS: This is a 
longitudinal study combining data from two government databases (Outpatient and 
Inpatient Information Systems—SIA/DATASUS and SIH/DATASUS) connected by 
deterministic linkage. Diagnosis of REs was done by International Classiﬁcation of 
Diseases (ICD-10) indicated on hospitalization. Kidney transplant patients from 7 
hospitals in Brazil in 2004 with at least one additional database record were followed 
for 60 months post-transplant. Duration of hospitalization, resource use and costs 
converted to 2004 USD of all REs were collected. Kaplan-Meier curves for the ﬁrst 
episode categorized by type of donor were calculated. RESULTS: From 1044 kidney 
transplant patients recorded in the database, 797 (410 deceased and 387 living) were 
eligible to the analysis. Proportion of patients that have not experienced any RE at 
12, 24, and 60 months were 73.2%; 69.6%; and 60.1% in the living group and 
72.1%; 70.0% and 66.0% in the deceased group. Kaplan-Meier curves, average length 
of stay (10.1 ± 8.2 days in the living group and 8.9 ± 8.5 days in the deceased group) 
and costs (US$715 ± 874 in the living group and US$651 ± 1,012 in the deceased 
group) of REs hospitalizations were not statistically different (p > 0.05). Total hospi-
talization costs were US$480,585. Hospital services (ICU/Ward days, operation room, 
equipments, etc) represent the most signiﬁcant portion of costs (43.1%), followed by 
diagnostic/laboratory tests (26.1%). Among transplant-related medications, tacroli-
mus, OKT3 and basiliximab accounted, respectively, for 4.4%, 2.2% and 1.1% of 
total expenses. CONCLUSIONS: A total of 73% of kidney transplanted patients did 
not have REs in the ﬁrst year post-transplant. Type of donor does not seem to inﬂuence 
occurrence, costs or duration of hospitalization.
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: Given recent safety as well as cost concerns, an evidence-based guide-
line for erythropoiesis stimulating agents (ESA) in chronic kidney disease (CKD) was 
developed across a seven-hospital system. The purpose of this analysis was to evaluate 
adherence to the guideline. Speciﬁc objectives were to assess: whether 1) optimal 
hemoglobin levels (10–12 g/dL) were achieved, 2) ferritin or transferrin saturation 
(TSAT) was measured; and 3) iron therapy was administered, when appropriate. 
METHODS: The Research Patient Data Registry, a repository comprised of over four 
million patients and 900 million inpatient and outpatient encounters, diagnoses, 
medications, laboratory tests and results, and other medical care served as the data 
source. Data were available for three hospitals, two academic medical centers and a 
community teaching hospital. Patients were eligible for inclusion if they had a diag-
nosis of CKD based on ICD-9 diagnosis code and received at least two doses of ESA 
within three months. The analysis timeframe was November 2007 to April 2008. 
RESULTS: During the 6-month period, 344 eligible patients were identiﬁed. Of these, 
54% achieved target hemoglobin levels within three months of therapy initiation. 
Approximately 4% did not have hemoglobin measured within three months. In the 
remaining patients, the hemoglobin level was less than 10 g/dL or more than 12 g/dL 
in 17% and 26% of patients, respectively. In 15% of patients neither ferritin nor 
TSAT were assessed. Among those with a ferritin < 100 ng/mL, 9% did not receive 
iron supplementation. TSAT was recorded only in one patient. CONCLUSIONS: 
Approximately half of the patients achieved target hemoglobin levels, highlighting 
the difﬁculty in maintaining target hemoglobin. These data suggest that adherence to 
this guideline can be improved in hemoglobin and iron monitoring and with iron 
supplementation.
URINARY/KIDNEY DISORDERS – Health Care Use & Policy Studies
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In 2011, a new prospective payment system will be instituted for Medicare payments 
for dialysis. CMS analyses revealed that dialysis payments differ signiﬁcantly by race, 
yet CMS has not proposed including a racial case mix adjuster (CMA). Initial analyses 
showed that the proposed payment system without a racial CMA produced signiﬁcant 
underpayment in dialysis units serving large numbers of black patients. OBJECTIVES: 
Model the impact of adding a racial case mix adjuster on dialysis reimbursement to 
clinics serving black patients, including a geospatial mapping to understand regional 
impact. METHODS: We used the racial case mix weights reported by CMS (though 
not included as a CMA), as well as the projected payments under the current and 
proposed payment systems. We used updated census data on race on the county level 
for a national analysis, and actual race for analysis of only DaVita clinics. We calcu-
lated clinic-level change in reimbursement using race CMA weights, then lowered the 
base payment rate to offset the incremental costs associated with the race CMA. We 
then use geomapping to plot percentage change due to race CMA, and overall change 
in proposed payment, and differential between current payment and proposed 
payment with and without the racial CMA. RESULTS: Among the 4276 dialysis 
clinics analyzed, the addition of the race CMA increased payment in 1140 clinics and 
decreased payments in 1206 clinics; it increased payment by ≥2% in 292 clinics and 
decreased payment by ≥2% in 172 clinics. Without the race CMA, payment reductions 
of ≥ 10% were disproportionately seen in areas in the southeast and in large cities 
with high percentages of blacks. This was ameliorated by the addition of the race case 
mix adjuster. CONCLUSIONS: CMS should include a race CMA in the prospective 
payment system for dialysis.
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The proposed Medicare prospective payment system for dialysis includes 18 case mix 
adjusters, 17 of which only increase payment. CMS calculated these adjusters using 
several data sources, including Medicare paid claims, and reduced the base payment 
22% to offset the associated incremental costs. OBJECTIVES: Determine the ability 
of a large dialysis organization to detect CMAs using all available data sources, and 
calculate the ﬁnancial impact of differences in CMAs ascertained by unit data, versus 
those reported by CMS. METHODS: Four dialysis units were randomly selected in 
each of 20 geographic regions. CMAs were ascertained via chart reviews, electronic 
medical records, hospital discharge summaries, paper charts, health care professional 
